Trident Texofab

Why is Trident Texofab Ltd falling/rising?

As of 19-Aug, Trident Texofab Ltd's stock price is 23.25, down 1.48%, and has underperformed its sector. The stock has seen a significant year-to-date decline of 90.07% and a drop in investor participation, indicating a bearish trend.

As of 19-Aug, Trident Texofab Ltd's stock price is currently at 23.25, reflecting a decrease of 0.35, or 1.48%. The stock has underperformed its sector by 1.57% today and has experienced a trend reversal, falling after two consecutive days of gains. Additionally, the stock's performance has been declining over the longer term, with a year-to-date drop of 90.07% and a one-year decline of 89.33%. <BR><BR>Investor participation has also decreased, as evidenced by a significant drop in delivery volume, which fell by 42.58% compared to the five-day average. While the stock is currently trading higher than its five-day moving averages, it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Overall, these factors contribute to the stock's current decline.

Which are the latest news on Trident Texofab?

Who are in the management team of Trident Texofab?

The management team of Trident Texofab includes Hardik J Desai (Chairman & Managing Director), Chetan C Jariwala (Whole-time Director), and several other directors and company secretaries, totaling 13 members with diverse expertise.

The management team of Trident Texofab includes the following individuals:<BR><BR>1. **Hardik J Desai** - Chairman & Managing Director<BR>2. **Chetan C Jariwala** - Whole-time Director<BR>3. **Maniya H Desai** - Director<BR>4. **Deepak P Gandhi** - Director<BR>5. **Natasha F Dsouza** - Independent Director<BR>6. **Ankita Jignesh Saraiya** - Independent Director<BR>7. **Vrusti B Patel** - Additional Independent Director<BR>8. **Manish Dhirajlaa Halwawala** - Additional Director<BR>9. **Rushi Hemantkumar Jagani** - Director<BR>10. **Mehul N Amareliya** - Company Secretary<BR>11. **Sanju Patel** - Company Secretary<BR>12. **Ashwinbhai Desai** - Additional Director<BR>13. **Mishal Shailesh Patel** - Additional Director<BR><BR>This team brings a diverse range of expertise to the company, contributing to its strategic direction and operations.

What does Trident Texofab do?

Trident Texofab Ltd is a Micro Cap company in the Garments & Apparels industry, incorporated in 2008 and converted to a Public Limited Company in 2017. As of June 2026, it reported net sales of 26 Cr and a net profit of 1 Cr, with a market cap of INR 33 Cr.

Overview: <BR>Trident Texofab Ltd operates in the Garments & Apparels industry and is categorized as a Micro Cap company.<BR><BR>History: <BR>Trident Texofab Ltd was originally incorporated as a Private Limited Company on September 05, 2008, and later converted into a Public Limited Company on June 06, 2017. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 26 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 1 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 33 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Industry P/E: 21 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.66 <BR>Return on Equity: 2.37% <BR>Price to Book: 0.59 <BR><BR>Contact Details: <BR>Address: 2004 2nd Flr North Extension, Nodh 4/1650 Sahara Darwaja Surat Gujarat : 395003 <BR>Tel: 91-261-2451284/2451274 <BR>Email: info@tridentexofab.com <BR>Website: http://www.tridenttexofab.com

Who are the peers of the Trident Texofab?

Trident Texofab's peers include Spenta Intl., Suryaamba Spinni, RSC Internl., Jaihind Industri, Tusaldah, Swasti Vinayaka, Pasupati Spinng., Super Spinning, and Akshar Spintex. Trident Texofab has the lowest 1-year return at -89.30%, significantly underperforming compared to its peers.

Peers: The peers of Trident Texofab are Spenta Intl., Suryaamba Spinni, RSC Internl., Jaihind Industri, Tusaldah, Swasti Vinayaka, Pasupati Spinng., Super Spinning, and Akshar Spintex.<BR><BR>Quality Snapshot: Excellent management risk is observed at Swasti Vinayaka, while Average management risk is found at Spenta Intl., Suryaamba Spinni, and the rest. Below Average management risk is noted for RSC Internl., Tusaldah, Pasupati Spinng., Super Spinning, and Akshar Spintex, while Jaihind Industri does not qualify. Growth ratings show Good growth at Pasupati Spinng., Below Average growth at Spenta Intl., Suryaamba Spinni, RSC Internl., Tusaldah, and the rest, while Jaihind Industri does not qualify. Capital Structure ratings indicate Good capital structure at Swasti Vinayaka, Below Average at Spenta Intl., RSC Internl., Tusaldah, Super Spinning, Akshar Spintex, and the rest, while Jaihind Industri does not qualify.<BR><BR>Return Snapshot: RSC Internl. has the highest 1-year return at 9.16%, while Trident Texofab has the lowest at -89.30%. This indicates that Trident Texofab's return is significantly lower than its peers. Additionally, the six-month returns for Suryaamba Spinni, Tusaldah, Swasti Vinayaka, Super Spinning, and Akshar Spintex are negative.

How big is Trident Texofab?

As of 14th August, Trident Texofab Ltd has a market capitalization of 33.11 Cr, classifying it as a Micro Cap company, with recent net sales of 116.08 Cr and a net profit of 0.21 Cr over the last four quarters.

As of 14th August, <BR><BR>Market Cap: Trident Texofab Ltd has a market capitalization of 33.11 Cr, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 116.08 Cr, while the sum of Net Profit for the same period is 0.21 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 47.24 Cr, and Total Assets amount to 100.58 Cr.

Should I buy, sell or hold Trident Texofab Ltd?

When is the next results date for Trident Texofab Ltd?

The next results date for Trident Texofab Ltd is 10 August 2026.

The next results date for Trident Texofab Ltd is scheduled for 10 August 2026.

Are Trident Texofab Ltd latest results good or bad?

Trident Texofab Ltd's latest results are concerning, showing a 12.14% year-on-year revenue decline and a net loss of ₹2.01 crores, leading to a "Strong Sell" recommendation due to negative operating margins and operational challenges.

Trident Texofab Ltd's latest results indicate a troubling performance. For the quarter ending March 2026, the company reported a revenue decline of 12.14% year-on-year, totaling ₹33.57 crores, despite a sequential improvement of 30.42% from the previous quarter. More concerning is the company's slip into operating losses, with an operating profit margin of -3.25%, a significant drop from the 3.56% margin achieved in the same quarter last year.<BR><BR>The net profit for this quarter was a loss of ₹2.01 crores, compared to a profit of ₹0.51 crores in the prior year, marking a drastic reversal in earnings. This decline raises serious concerns about the company's competitive positioning and cost structure, especially given the typically strong demand in the textile sector during this period.<BR><BR>Overall, the results reflect significant operational challenges and a deterioration in financial health, leading to a "Strong Sell" recommendation for investors. The company faces multiple red flags, including negative operating margins and weak capital efficiency, which overshadow any potential positives from sequential revenue recovery.

Is Trident Texofab overvalued or undervalued?

As of December 4, 2025, Trident Texofab is considered very expensive with a PE ratio of 171.99 and significantly higher valuation metrics compared to its peers, indicating that its impressive stock performance may not be justified by its fundamentals.

As of 4 December 2025, the valuation grade for Trident Texofab has moved from expensive to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE ratio of 171.99, an EV to EBITDA of 65.76, and a PEG ratio of 18.66, all of which are considerably higher than industry norms. <BR><BR>In comparison to its peers, Elitecon International has a PE ratio of 197.4, while Lloyds Enterprises stands at 24.29, highlighting the stark contrast in valuation metrics within the sector. Despite Trident Texofab's impressive stock performance, with a year-to-date return of 102.05% compared to the Sensex's 9.12%, the current valuation suggests that investors may be paying a premium that is not justified by the company's fundamentals.

Is Trident Texofab technically bullish or bearish?

As of December 3, 2025, the trend is mildly bullish, supported by daily moving averages and Bollinger Bands, though caution is advised due to a mildly bearish weekly MACD and bearish monthly RSI.

As of 3 December 2025, the technical trend has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by the daily moving averages indicating mild bullishness and the Bollinger Bands showing a mildly bullish trend on both weekly and monthly time frames. However, the weekly MACD is mildly bearish and the monthly RSI is bearish, which suggests some caution. The KST remains bullish on both weekly and monthly charts, providing some support to the mildly bullish outlook. Overall, while there are mixed signals, the prevailing trend is mildly bullish.

How has been the historical performance of Trident Texofab?

Trident Texofab has shown steady growth in net sales, increasing from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25, with profits also rising significantly. However, cash flow from operating activities turned negative in Mar'25, indicating challenges in cash management despite overall financial growth.

Answer:<BR>The historical performance of Trident Texofab shows a steady increase in net sales and overall financial growth over the years.<BR><BR>Breakdown:<BR>Trident Texofab's net sales have shown a consistent upward trend, rising from 49.93 Cr in Mar'21 to 122.06 Cr in Mar'25. Total operating income followed a similar pattern, reaching 122.06 Cr in Mar'25, up from 90.96 Cr in Mar'20. The company's total expenditure, excluding depreciation, also increased, amounting to 116.58 Cr in Mar'25, compared to 47.05 Cr in Mar'21. Operating profit (PBDIT) has fluctuated, peaking at 8.78 Cr in Mar'25, while profit before tax reached 2.58 Cr in the same year. Profit after tax has also improved, standing at 2.51 Cr in Mar'25, up from 0.35 Cr in Mar'21. The company's total assets grew significantly from 55.68 Cr in Mar'20 to 100.58 Cr in Mar'25, while total liabilities increased from 20.37 Cr to 26.50 Cr during the same period. Cash flow from operating activities turned negative in Mar'25 at -13.00 Cr, contrasting with positive cash flows in previous years. Overall, Trident Texofab has demonstrated growth in sales and profits, despite some challenges in cash flow management.

Who are the top shareholders of the Trident Texofab?

The top shareholder of Trident Texofab is promoter Hardik Jigishkumar Desai with 14.15%, followed by public shareholder Savitriben Mahendrabhai Shah at 1.44%. Individual investors collectively hold 59.36%, with no institutional or pledged promoter holdings.

The top shareholders of Trident Texofab include Hardik Jigishkumar Desai, who is the promoter with the highest holding at 14.15%. The highest public shareholder is Savitriben Mahendrabhai Shah, holding 1.44%. Additionally, individual investors collectively hold a significant portion of 59.36%. There are no institutional holdings from mutual funds or foreign institutional investors, and there are no pledged promoter holdings.

What is the bonus history of the Trident Texofab?

Trident Texofab issued a bonus on August 11, 2020, in the ratio of 14:10, granting shareholders 14 additional shares for every 10 shares held, with a record date of August 12, 2020.

Trident Texofab has a bonus history that includes a notable issue on August 11, 2020. The company announced a bonus in the ratio of 14:10, meaning that for every 10 shares held, shareholders received an additional 14 shares. The record date for this bonus was August 12, 2020. If you have any more questions about Trident Texofab or need further details, feel free to ask!

Has Trident Texofab declared dividend?

Yes, Trident Texofab Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of July 18, 2019. However, the dividend yield is 0%, as there have been no dividend returns in recent periods, despite strong price returns.

Trident Texofab Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 18 Jul 19<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 Months period, the price return was 57.14%, the dividend return was 0%, resulting in a total return of 57.14%.<BR><BR>In the 1 Year period, the price return was 356.13%, the dividend return was 0%, resulting in a total return of 356.13%.<BR><BR>In the 2 Years period, the price return was 234.83%, the dividend return was 0%, resulting in a total return of 234.83%.<BR><BR>In the 3 Years period, the price return was 101.25%, the dividend return was 0%, resulting in a total return of 101.25%.<BR><BR>In the 4 Years period, the price return was 460.32%, the dividend return was 0%, resulting in a total return of 460.32%.<BR><BR>In the 5 Years period, the price return was 545.26%, the dividend return was 0%, resulting in a total return of 545.26%.<BR><BR>Overall, Trident Texofab has declared a dividend, but it has not contributed to any yield in recent periods, as indicated by the 0% dividend yield. The company has shown strong price returns across all periods, suggesting robust performance despite the lack of ongoing dividends.